a Regenerative Medicine Laboratory, BioCruces Health Research Institute, Cruces University Hospital , Barakaldo , Spain.
b Department of Musculoskeletal Disorders , University of Salerno School of Medicine and Dentristry , Salerno , Italy.
Expert Opin Biol Ther. 2018 Jul;18(7):785-793. doi: 10.1080/14712598.2018.1492541. Epub 2018 Jul 9.
Regular engagement in sports produces many health benefits, but also exposes to increased injury risk. The quality of medical care available is crucial not only for sports trauma but also to avoid overuse syndromes and post-traumatic degenerative conditions.
We provide background information on some clinical needs in sport injuries and describe the main families of biological products used in clinical practice. We also discuss limitations of the current clinical experience.
Sport and exercise impairment affects different segments of the population with different needs. The exceptional demands of elite athletes and subsequent media coverage have created hype around regenerative therapies. Statistical evidence, whether weak (cell products) or moderate (PRPs), is not enough to drive medical decisions because of the heterogeneity of the biological products available and their application procedures. Moreover, the specific needs of the different segments of the population along with the available clinical evidence for each musculoskeletal condition should be considered in the decision-making process. There is urgent need to develop regenerative protocols combined with post-intervention rehabilitation, and gather meaningful clinical data on the safety and efficacy of these interventions in the different populations segments.
定期参与体育运动有许多健康益处，但也会增加受伤风险。医疗质量不仅对于运动创伤至关重要，对于避免过度使用综合征和创伤后退行性疾病也至关重要。
我们提供运动损伤中一些临床需求的背景信息，并描述临床实践中使用的主要生物制品家族。我们还讨论了当前临床经验的局限性。
运动和锻炼损伤影响到不同人群，他们有不同的需求。精英运动员的特殊要求以及随后的媒体报道围绕着再生疗法产生了炒作。统计证据（无论是细胞产品的弱证据还是 PRPs 的中等证据）都不足以推动医疗决策，因为可用的生物制品及其应用程序存在异质性。此外，在决策过程中，应考虑不同人群的具体需求以及针对每种肌肉骨骼疾病的现有临床证据。迫切需要制定再生方案，结合干预后的康复，并在不同人群中收集这些干预措施的安全性和有效性的有意义的临床数据。
